Lupin in alliance with Natco Pharma has received final ANDA approval for Imatinib Mesylate Tablets, 100 mg (base) and 400 mg (base) from the United States Food and Drug Administration (USFDA) to market a generic version of Novartis Pharmaceuticals Corporation's (Novartis) Gleevec Tablets, 100mg and 400mg.
Lupin and Natco's Imatinib Mesylate Tablets, 100 mg (base) and 400 mg (base) is the generic version of Novartis' Gleevec Tablets, 100 mg and 400 mg. Imatinib Mesylate Tablets, 100 mg (base) and 400 mg (base) had annual sales of approximately $655 mn in the US (IQVIA MAT December 2018).
Lupin’s state-of-the-art Mihan facility at Nagpur commissioned recently has the production capabilities for injectables with vials, Iyophilised vials and Pre-filled Syringes (PFS). It received an EIR from USFDA in December 2018.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: